

OnSite INSIGHTS

Volume 2, Issue 1, 2015

CTK to Launch Two Hepatitis Rapid Tests in Observation of World Hepatitis Day

Hepatitis is a potentially fatal disease of the liver that affects one in 12 people worldwide. The symptoms are often hidden and the disease goes undiagnosed and untreated. About 1 million people die every year because of viral hepatitis infections. Types B and C are especially serious and lead to chronic infection in millions of people, and, together, are the most common cause of cirrhosis and cancer of the liver. On July 28th, World Hepatitis Day (WHD) is recognized throughout the world and is one of the eight designated health days endorsed by the World Health Organization.

This year on World Hepatitis Day, CTK Biotech will be launching two new Hepatitis Rapid Tests, HAV IgG/IgM and HEV IgG/IgM, in addition to our existing HAV, HBV, HCV and HEV products. The uniqueness of these new tests is the detection of IgG and IgM in a single device allowing users to diagnose the presence of infection and determine the stage of infection. This distinguishing feature enhances the ability to make the correct diagnosis and guide clinical management of patients.

“CTK’s new hepatitis rapid tests will fulfill the need of reliable, POCT hepatitis diagnosis.”

Dr. Catherine Chen, CEO, CTK

Completion of Our TORCH Panel Product Line



We are pleased to announce the addition of two more rapid tests, HSV-1 IgG/IgM and HSV-2 IgG/IgM. With this addition we will have a complete product line dedicated to prenatal care including Toxoplasmosis, Rubella and Cytomegalovirus.

Although HSV-1 and HSV-2 are typically asymptomatic or cause only mild symptoms in the mother, they can cause serious complications to the fetus, especially if the infection occurs during the first three months of pregnancy. The risk during primary infection is much higher compared with a reactivated infection.

Our TORCH line products are first of their kind on the market that accurately differentiate between IgG and IgM enabling detection of acute, present and past infection. Accurate detection of IgG and IgM antibodies during medical visits help to determine appropriate follow up, improving patient health and better monitoring of at-risk pregnancies.

Hepatitis Products	P.1
TORCH Products	P.1
Dengue Campaign	P.2
Colorectal Cancer Care	P.2
Brazil Audit success	P.3
Company Express	P.3
Upcoming Events	P.3

CTK Emerges as A Leader in Dengue Diagnosis

An estimated 100 million cases of dengue fever and 250,000 cases of life-threatening dengue hemorrhagic fever occur globally every year. There is no specific treatment or vaccine available, however, early detection and proper medical care reduce fatality rates to below 1%. CTK Biotech meets the need of early and accurate detection with a complete line of dengue testing kits, including rapid tests, ELISA tests, and external test control, for screening of all phases of infection. In addition, CTK produces a complete line of dengue reagents, including 4 serotype recombinant E proteins, 4 serotype recombinant NS1 proteins, and antibodies, for manufacturing high quality tests.

Recently, an external evaluation was performed in an ISO certified laboratory in Colombia, comparing CTK's Dengue Duo Ag-IgG/IgM rapid test (R0062C) with the most popular test on the market. In this well designed external evaluation, the overall agreement for detection of IgG, IgM, and NS1 by CTK rapid test with the competitor test were 90% or above. The true nature of the specimens which yielded conflicting test results was determined by confirmatory ELISA tests. Among the 7 conflicting results, confirmatory ELISA tests showed that 6 specimens were correctly identified by CTK rapid tests, while only 1 was correctly identified by the competitor test. Therefore, CTK Dengue Duo Ag-IgG/IgM rapid rest is a more accurate screening tool.

Raw data of testing by CTK's rapid test vs. competitor test

SAMPLE	Dengue IgG Results			Dengue IgM Results			Dengue NS1 Results		
	CTK	Competitor	IgG ELISA	CTK	Competitor	IgM ELISA	CTK	Competitor	NS1 ELISA
1310879	Pos.	Neg.	Pos.	Pos.	Pos.		Pos.	Pos.	
8140725	Pos.	Neg.	Pos.	Neg.	Neg.		Pos.	Pos.	
2063258	Pos.	Pos.		Pos.	Neg.	Pos.	Neg.	Neg.	
8151948	Neg.	Neg.		Pos.	Neg.	Pos.	Pos.	Pos.	
1204206	Pos.	Pos.		Pos.	Pos.		Neg.	Pos.	Neg.
8130505	Pos.	Pos.		Pos.	Pos.		Neg.	Pos.	Neg.
8142881	Neg.	Neg.		Neg.	Neg.		Pos.	Neg.	Neg.

Please inquire with your sales representative or CTK's website NEWS section to review the entire case report.

Colorectal Cancer: Detect It Early with iFOB Test




Colorectal cancer causes 15% of all cancer-related deaths, second only to lung cancer. More than 95% of colon cancer progresses from small lumps of cells called NEOPLASTIC POLYPS. The polyps do not often cause noticeable symptoms, but may lead to a trace amount of bleeding that is not detectable by the naked eye. An effective test to detect this trace amount of bleeding facilitates early intervention and a reduction in colorectal cancer mortality.

The American Cancer Association (ACA) recommends annual iFOB screening tests at age 50, or age 45 for those with a family history of colorectal cancer. iFOB screening can help catch polyps prompting surgical removal before they progress into cancer.

The Guaiac FOB test is recognized by ACA as neither sensitive nor accurate in comparison with the iFOB test. In combating cancer, CTK's strategy is to offer simple cancer screening tests, which are accessible at any place and at any time by any laboratory or clinic in metropolitan or remote areas.

To learn more about colorectal cancer and the CTK Cancer Care Program, please request CTK's informative iFOB booklet from your sales representative or e-mail to: marketing@ctkbiotech.com.



Brazil Audit Success

CTK Biotech has passed GMP inspection and received authorization by the Brazilian Health Surveillance Agency (ANVISA), allowing our tests to be used in the Brazilian healthcare market.



“ Our goal is to bring affordable and convenient diagnostics to the Brazilian people. This ANVISA approval allows us to achieve this goal with our top-of-the-line rapid tests and ELISA kits. ”

Dr. Catherine Chen, CEO, CTK



CTK is Here to Support You

Please visit our award-winning website, an essential resource where you can quickly find valuable information. Not only can you stay up-to-date on our full product range and associated features but you can keep abreast of disease trends and global intervention strategies by CDC, WHO, and other health care authorities. Moreover, please browse our growing collection of third party publications where CTK's product performance is documented in scientifically sound clinical studies. For your convenience, the digital marketing and training materials including disease introductions, product features, and market landscape analyses, are available for immediate download. We also provide multi-lingual versions of support materials for our worldwide clients.

CTK's tailored sales training empowers our distribution partners to achieve fast and effective market penetration through in-person and on-line support from our experienced PhD-level Product Managers and MBA-level sales strategists. Our rapidly growing team also provides simplified, but comprehensive test-feature and procedure training for end users resulting in maximum test result reliability. Strategic co-sponsorship of CME conferences to update local physicians, pathologists, and lab managers on the newest diagnostic trends in the USA is just one more of the many ways CTK supports our clients. Please e-mail your sales representative or tech@ctkbiotech.com for more information.

Meet us

- Indonesian Hospital Expo, Oct 2015
- Medica, Germany, Nov 2015
- Arab Health, Dubai, Jan 2016

Address: 10110 Mesa Rim Road
San Diego, CA 92121

E-mail: info@ctkbiotech.com

Web: www.ctkbiotech.com

Phone: 858-457-8698

Fax: 858-535-1739